Showing results (121-130 of 163) with videos related to
Sort By:
Pageof 17
Cancer Medicine|April 20, 2022
Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysisToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Cancer Medicine|December 9, 2022
New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation studyToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Cancer Medicine|September 26, 2022
The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC-GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysisTakeshi Hatanaka, Atsushi Naganuma, Atsushi Hiraoka, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 26, 2022
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysisTakeshi Hatanaka, Atsushi Hiraoka, Toshifumi Tada, et al.Cancer Medicine|December 15, 2022
Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumabToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Hepatology International|September 8, 2022
Development and validation of a modified albumin-bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumabTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.European Journal of Gastroenterology & Hepatology|February 16, 2022
Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysisToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 6, 2023
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysisTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.Journal of Gastroenterology and Hepatology|January 6, 2025
Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk ModelsTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.Liver Cancer|August 21, 2023
Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter AnalysisAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Pageof 17